Start Global Navigation

  1. Home
  2. About RCAST
  3. Research
  4. Industry-Academia-Government Collaboration
  5. International Collaboration

Start Main Contents

RCAST Report

Press Release:
UTokyo concludes agreement to develop personalized cancer vaccine
Research collaboration focusing on a novel method for neoantigen identification

The University of Tokyo entered an agreement for developing a personalized cancer vaccine using a novel method involving the body’s immune response. The collaborative research agreement was concluded with the Kanagawa Cancer Center in Yokohama and BrightPath Biotherapeutics, a biopharmaceutical company based in Tokyo.

The collaboration consisting of genomic, proteomic (studying the set of proteins produced by a certain genome) and immunology research is led by Professor Hiroyuki Aburatani and Associate Professor Takeshi Kawamura of the University of Tokyo, with Dr. Tetsuro Sasada, director of the Cancer Vaccine Center at the Kanagawa Cancer Center, and BrightPath also participating.

LinkOUT  Press Release

Start Site Information

page top

Copyright (c) RCAST, The University of Tokyo